Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Cytoxan (cyclophosphamide)
- Gliadel (carmustine)
Interactions between your drugs
cycloPHOSphamide carmustine
Applies to: Cytoxan (cyclophosphamide), Gliadel (carmustine)
MONITOR: Limited animal data and limited observations of humans suggest that cyclophosphamide and/or cisplatin may increase plasma carmustine (BCNU) levels. It is suspected that cisplatin can decrease the metabolism of BCNU. Blood BCNU levels are positively correlated with a steroid-responsive pulmonary injury seen in patients treated with BCNU, and pretreatment or concomitant therapy with cyclophosphamide and/or cisplatin may increase the risk.
MANAGEMENT: Close monitoring for signs of pulmonary toxicity is recommended during treatment.
References (2)
- Jones RB, Matthes S, Dufton C, et al. (1993) "Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer." Breast Cancer Res Treat, 26, S11-7
- Fassas A, Gojo I, Rapoport A, et al. (2001) "Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy." Bone Marrow Transplant, 28, p. 399-403
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is used for the treatment of relapsed or refractory multiple ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.